Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy (ImPACCT)
Targeted Therapy With Imatinib for Treatment of Poor Prognosis Mesenchymal-type Resectable Colon Cancer: a Proof-of-concept Study in the Preoperative Window Period.
Sponsor: Erasmus Medical Center
Terminated
Low accrual rate
Other terminated trials from Erasmus Medical Center
Other Colonic Neoplasms trials with similar outcome
A PHASE2 clinical study on Colonic Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Erasmus Medical Center and has accumulated 6 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2018 — Nov 2019 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Erasmus Medical Center
- Hubrecht Institute
- Meander Medical Center
- UMC Utrecht
For direct contact, visit the study record on ClinicalTrials.gov .